Mesangiolysis in Chronic Active Antibody-mediated Rejection in Kidney Transplant Biopsies

被引:0
|
作者
Suto, Yuki [1 ]
Oguchi, Hideyo [1 ,6 ]
Tochigi, Naobumi [2 ]
Mikami, Tetuo [3 ]
Shinoda, Kazunobu [1 ,4 ]
Honda, Kazuho [5 ]
Kounoue, Noriyuki [1 ]
Hashimoto, Junya [1 ]
Muramatsu, Masaki [1 ]
Itabashi, Yoshihiro [1 ]
Sakai, Ken [1 ]
机构
[1] Toho Univ, Fac Med, Dept Nephrol, Tokyo, Japan
[2] Toho Univ, Fac Med, Dept Surg Pathol, Tokyo, Japan
[3] Toho Univ, Fac Med, Dept Pathol, Tokyo, Japan
[4] St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa, Japan
[5] Showa Univ, Sch Med, Dept Anat, Tokyo, Japan
[6] Toho Univ, Fac Med, Dept Nephrol, 6-11-1 Omori Nishi, Ota ku, Tokyo 1438541, Japan
关键词
CLASSIFICATION; INJURY;
D O I
10.1159/000531573
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study aimed to determine if immune or non-immune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies. Methods: We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification. Multivariate logistic regression analysis was performed using a forward selection method. Results: Fifteen of the 41 P-CAABMR biopsies (36.6%) cases showed MGLS. The estimated glomerular filtration rate (eGFR) was significantly lower in the MGLS-positive compared with the MGLS-negative group, and proteinuria was significantly higher in the MGLS-positive compared with the MGLS-negative group. In the clinical model, multivariate analysis was performed using covariates of eGFR and duration after transplantation significantly correlated with MGLS by simple analysis, in addition to type of calcineurin inhibitor use (tacrolimus or cyclosporine), donor-specific antibodies, diabetes, and hypertension grade defined by use of antihypertensive therapy or/and blood pressure level. Only hypertension grade was significantly correlated with MGLS. In the pathological model, multivariate analysis was performed using the presence of FSGS and the aah and cg scores significantly correlated with MGLS by simple analysis, in addition to g and ptc scores. The cg score was significantly correlated with hypertension grade, duration after transplantation, g, ah and aah. Conclusion: Lower graft function and higher proteinuria was observed in MGLS of P-CAABMR. The Banff cg score was independently related to MGLS in multivariate analysis. Sustained glomerulitis, calcineurin inhibitor nephrotoxicity, and hypertension may cause Banff cg lesions, leading to MGLS in P-CAABMR.
引用
收藏
页码:14 / 21
页数:19
相关论文
共 50 条
  • [41] Not all transplant glomerulopathy related to chronic antibody-mediated rejection
    Akalin, Enver
    Silva, Mariel Barbachan e
    Mustofa, Sadia
    Bao, Yi
    Broin, Pilib o
    TRANSPLANTATION, 2024, 108 (9S)
  • [42] Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation
    Nickerson, Peter W. W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 38 - 44
  • [43] Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation
    Muller, Yannick D.
    Ghaleb, Nseir
    Rotman, Samuel
    Vionnet, Julien
    Halfon, Matthieu
    Catana, Emmanuelle
    Golshayan, Dela
    Venetz, Jean-Pierre
    Aubert, Vincent
    Pascual, Manuel
    TRANSPLANT INTERNATIONAL, 2018, 31 (04) : 451 - 455
  • [44] RITUXIMAB AS MONOTHERAPY FOR THE TREATMENT OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION
    Muller, Yannick
    Ghaleb, Nseir
    Rotman, Samuel
    Catana, Emmanuelle
    Golshayan, Dela
    Venetz, Jean-Pierre
    Aubert, Vincent
    Pascual, Manuel
    TRANSPLANT INTERNATIONAL, 2017, 30 : 553 - 554
  • [45] Chronic Active Antibody-Mediated Rejection Following COVID-19 Infection in a Kidney Transplant Recipient: A Case Report
    Abuzeineh, Mohammad
    Tariq, Anam
    Rosenberg, Avi
    Brennan, Daniel C.
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (04) : 1202 - 1206
  • [46] Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
    Nickerson, P.
    Boehmig, G.
    Chadban, S.
    Kumar, D.
    Mannon, R. B.
    Van Gelder, T.
    Adler, S.
    Chong, E.
    Djamali, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 737 - 737
  • [47] Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection
    Ban, Tae Hyun
    Yu, Ji Hyun
    Chung, Byung Ha
    Choi, Bum Soon
    Park, Cheol Whee
    Kim, Yong-Soo
    Yang, Chul Woo
    ANNALS OF TRANSPLANTATION, 2017, 22 : 468 - 474
  • [48] Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
    Pottebaum, April A.
    Venkatachalam, Karthikeyan
    Liu, Chang
    Brennan, Daniel C.
    Murad, Haris
    Malone, Andrew F.
    Alhamad, Tarek
    TRANSPLANTATION DIRECT, 2020, 6 (04): : E543
  • [49] Antibody-mediated lung transplant rejection
    Ramsey Hachem
    Current Respiratory Care Reports, 2012, 1 (3): : 157 - 161
  • [50] LATE ANTIBODY-MEDIATED REJECTION AND TRANSPLANT GLOMERULOPATHY: HOW TO AVOID CHRONIC REJECTION?
    Ferrari-Lacraz, Sylvie
    Bouatou, Yassine
    Ponte, Belen
    Moll, Solange
    Martin, Pierre-Yves
    Villard, Jean
    Hadaya, Karine
    TISSUE ANTIGENS, 2014, 84 (01): : 95 - 96